|50.60||-0.2700||-0.53%||Vol 6.33M||1Y Perf 253.02%|
|Aug 11th, 2022 16:00 DELAYED|
|- -||0.06 0.12%|
|Target Price||73.83||Analyst Rating||Hold 2.71|
|Potential %||45.91||Finscreener Ranking||+ 36.88|
|Insiders Trans % 3/6/12 mo.||-100/-100/-100||Value Ranking||★★ 45.55|
|Insiders Value % 3/6/12 mo.||-100/-100/-100||Growth Ranking||★ 36.62|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-100||Income Ranking||— -|
|Price Range Ratio 52W %||99.10||Earnings Rating||Neutral|
|Market Cap||3.61B||Earnings Date||9th Aug 2022|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Buy|
|Mngmt Effectiveness||Value||Industry||S&P 500||US Markets|
ROE (5Y Avg)
ROE last 12 Months
ROA (5Y Avg)
ROA last 12 Months
ROC (5Y Avg)
ROC last 12 Months
Return on invested Capital Q
Return on invested Capital Y
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||-|
|Estimated EPS Next Report||-0.51|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||12.26M|
|Avg. Monthly Volume||3.31M|
|Avg. Quarterly Volume||2.00M|
ChemoCentryx Inc. (NASDAQ: CCXI) stock closed at 50.6 per share at the end of the most recent trading day (a -0.53% change compared to the prior day closing price) with a volume of 6.33M shares and market capitalization of 3.61B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 82 people. ChemoCentryx Inc. CEO is Thomas J. Schall.
The one-year performance of ChemoCentryx Inc. stock is 253.02%, while year-to-date (YTD) performance is 38.97%. CCXI stock has a five-year performance of 602.78%. Its 52-week range is between 13.11 and 50.94, which gives CCXI stock a 52-week price range ratio of 99.10%
ChemoCentryx Inc. currently has a PE ratio of -11.40, a price-to-book (PB) ratio of 6.31, a price-to-sale (PS) ratio of 62.55, a price to cashflow ratio of 40.20, a PEG ratio of 2.32, a ROA of -30.85%, a ROC of -36.42% and a ROE of -46.91%. The company’s profit margin is -92.18%, its EBITDA margin is -493.80%, and its revenue ttm is $25.44 Million , which makes it $0.36 revenue per share.
Of the last four earnings reports from ChemoCentryx Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.51 for the next earnings report. ChemoCentryx Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for ChemoCentryx Inc. is Hold (2.71), with a target price of $73.83, which is +45.91% compared to the current price. The earnings rating for ChemoCentryx Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
ChemoCentryx Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
ChemoCentryx Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 12.84, ATR14 : 2.47, CCI20 : 111.54, Chaikin Money Flow : 0.00, MACD : 7.11, Money Flow Index : 88.98, ROC : 120.77, RSI : 79.54, STOCH (14,3) : 98.42, STOCH RSI : 0.98, UO : 86.76, Williams %R : -1.58), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of ChemoCentryx Inc. in the last 12-months were: Geoffrey M. Parker (Option Excercise at a value of $180 250), Henry A. McKinnell (Option Excercise at a value of $0), James L. Tyree (Option Excercise at a value of $0), James L. Tyree (Sold 13 863 shares of value $601 329 ), Joseph M. Feczko (Option Excercise at a value of $577 750), Markus J. Cappel (Option Excercise at a value of $0), Markus J. Cappel (Sold 7 564 shares of value $379 864 ), Rita I. Jain (Option Excercise at a value of $0), Susan M. Kanaya (Option Excercise at a value of $300 805), Susan M. Kanaya (Sold 46 298 shares of value $2 322 715 ), Thomas J. Schall (Option Excercise at a value of $1 856 400), Thomas J. Schall (Sold 130 000 shares of value $6 531 733 )
Tue, 09 Aug 2022 13:40 GMT Analysts Offer Insights on Healthcare Companies: ChemoCentryx (CCXI) and ATI Physical Therapy (ATIP)- TipRanks. All rights reserved.
Wed, 01 Jun 2022 10:15 GMT Analysts Top Healthcare Picks: ChemoCentryx (CCXI), MannKind (MNKD)- TipRanks. All rights reserved.
Sun, 22 May 2022 08:46 GMT Can ChemoCentryx Control Challenging Capital Complications- TipRanks. All rights reserved.
Sun, 08 May 2022 15:19 GMT ChemoCentryx (CCXI) Gets a Buy Rating from SVB Securities- TipRanks. All rights reserved.
Wed, 02 Mar 2022 11:25 GMT Analysts Are Bullish on These Healthcare Stocks: ChemoCentryx (CCXI), Taro Pharmaceutical (TARO)- TipRanks. All rights reserved.
Tue, 15 Feb 2022 16:15 GMT ChemoCentryx (CCXI) Receives a Buy from H.C. Wainwright- TipRanks. All rights reserved.
Wed, 19 Jan 2022 14:35 GMT ChemoCentryx (CCXI) Received its Third Buy in a Row- TipRanks. All rights reserved.
Tue, 18 Jan 2022 15:45 GMT ChemoCentryx (CCXI) Gets a Buy Rating from Leerink Partners- TipRanks. All rights reserved.
Copyright © 2016-2022 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.